Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

RCEL


Top 10 Correlated ETFs

RCEL


Top 10 Correlated Stocks

RCEL


In the News

04:01 29 Nov 2022 RCEL

AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference

VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time.

10:15 29 Nov 2022 RCEL

AVITA Medical, Inc. (RCEL) Q3 2022 Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Charlie Montang - Lake Street Capital Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Joshua Jennings - Cowen Madeleine Williams - Wilsons Operator Good day and thank you for standing by and welcome to AVITA Medical Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

04:01 29 Nov 2022 RCEL

AVITA Medical to Announce Third Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 11, 2022, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent highlights.

09:03 29 Nov 2022 RCEL

AVITA Medical, Inc. (RCEL) CEO Dr. Mike Perry on Q2 2022 Results - Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2022 Results Conference Call August 11, 2022 5:00 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Dr. Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Ryan Zimmerman - BTIG Operator Hello. Thank you for standing by and welcome to the AVITA Medical Inc. Second Quarter 2022 Earnings Conference Call.

04:01 29 Nov 2022 RCEL

AVITA Medical to Announce Second Quarter 2022 Financial Results

VALENCIA, Calif., and MELBOURNE, Australia, July 25, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time (Friday, August 12, 2022 at 7:00 a.m. Australian Eastern Standard Time) to discuss its financial results and recent highlights.

10:19 29 Nov 2022 RCEL

AVITA Medical, Inc. (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Lyanne Harrison - Bank of America John Hester - Bell Potter Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2022 Conference Call.

04:01 29 Nov 2022 RCEL

AVITA Medical to Announce First Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (Friday, May 13, 2022 at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent highlights.

09:44 29 Nov 2022 RCEL

AVITA Medical Inks Supply Pact With Premier For RECELL System

AVITA Medical Inc (NASDAQ: RCEL) has been awarded a group purchasing agreement with Premier Inc (NASDAQ: PINC) The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the RECELL System for.

08:55 29 Nov 2022 RCEL

AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript

AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript

04:01 29 Nov 2022 RCEL

AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Dr. Mike Perry, CEO, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Standard Time (Wednesday, March 9, 2022 at 4:50 a.m. Australian Eastern Daylight Time).

Financial details

Company Rating
Buy
Market Cap
167.46M
Income
-29.79M
Revenue
31.9M
Book val./share
3.52
Cash/share
3.37
Dividend
-
Dividend %
-
Employees
116
Optionable
No
Shortable
Yes
Earnings
10 Nov 2022
P/E
-32.32
Forward P/E
-3.3
PEG
7.6
P/S
5.24
P/B
1.9
P/C
1.99
P/FCF
-5.6
Quick Ratio
9.22
Current Ratio
9.64
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-1.19
EPS next Y
-2.03
EPS next Q
-0.66
EPS this Y
-43.48%
EPS next Y
70.17%
EPS next 5Y
70.17%
EPS last 5Y
0.02%
Revenue last 5Y
100.27%
Revenue Q/Q
9.08%
EPS Q/Q
-12%
-
-
-
-
SMA20
46.72%
SMA50
13.65%
SMA100
33.09%
Inst Own
17.26%
Inst Trans
-3.22%
ROA
-30%
ROE
-31%
ROC
-0.34%
Gross Margin
83%
Oper. Margin
-97%
Profit Margin
-93%
Payout
-
Shs Outstand
25.03M
Shs Float
123.07M
-
-
-
-
Target Price
-
52W Range
4.41-14.36
52W High
-52.14%
52W Low
+67.5%
RSI
58.76
Rel Volume
0.99
Avg Volume
83.85K
Volume
83.29K
Perf Week
-9.7%
Perf Month
47.9%
Perf Quarter
16.32%
Perf Half Y
17.54%
-
-
-
-
Beta
0.785014
-
-
Volatility
0.25%, 1.07%
Prev Close
0.15%
Price
6.7
Change
-5.63%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-06-30

Metric History 2017-06-302018-06-302019-06-302020-06-30 2021-06-30
Revenue per share
0.120.090.430.71.29
Net income per share
-1.16-1.3-1.94-2.07-1.17
Operating cash flow per share
-1.12-1.28-1.52-1.12-1.14
Free cash flow per share
-0.9-1.32-1.62-1.16-1.19
Cash per share
0.381.161.63.634.88
Book value per share
0.511.491.653.575.1
Tangible book value per share
0.511.491.633.555.08
Share holders equity per share
0.511.491.653.575.1
Interest debt per share
00.010.0100.04
Market cap
50.89M58.07M375.56M431.99M420.16M
Enterprise value
47.98M47.28M355.3M358.36M310.29M
P/E ratio
-5.75-4.79-15.25-10.28-15.81
Price to sales ratio
56.165.9469.630.2914.37
POCF ratio
-5.95-4.83-19.51-18.99-16.22
PFCF ratio
-7.37-4.69-18.31-18.31-15.52
P/B Ratio
12.934.16185.973.63
PTB ratio
12.934.16185.973.63
EV to sales
52.8953.6865.8425.1210.61
Enterprise value over EBITDA
-5.05-3.63-14.53-8.63-12.02
EV to operating cash flow
-5.61-3.93-18.46-15.75-11.98
EV to free cash flow
-6.95-3.81-17.33-15.19-11.46
Earnings yield
-0.17-0.21-0.07-0.1-0.06
Free cash flow yield
-0.14-0.21-0.05-0.05-0.06
Debt to equity
00.01000.01
Debt to assets
0.330.170.190.120.08
Net debt to EBITDA
0.310.830.831.774.26
Current ratio
2.865.745.510.1716.42
Interest coverage
-1.53K-675.05-946.78-1.29K-1.21K
Income quality
0.970.990.780.540.97
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
10.2462.352.430.77
Research and developement to revenue
3.9710.521.860.590.51
Intangibles to total assets
000.0100
Capex to operating cash flow
0.040.030.070.040.05
Capex to revenue
-0.37-0.42-0.23-0.06-0.04
Capex to depreciation
-2.38-3.47-4.75-1.82-1.64
Stock based compensation to revenue
000.361.160.19
Graham number
3.666.598.4912.911.6
ROIC
-3.81-0.94-1.17-0.57-0.22
Return on tangible assets
-1.5-0.72-0.97-0.51-0.21
Graham Net
0.331.211.373.254.75
Working capital
3.64M13.51M19.82M70.68M113.94M
Tangible asset value
0020.64M72.04M115.18M
Net current asset value
3.64M13.41M19.35M68.33M111.48M
Invested capital
00.01000.01
Average receivables
2.01M3.21M2.26M2.43M5.16M
Average payables
2.55M2.27M2.4M4.33M3.73M
Average inventory
961.13K987.03K932.9K1.13M1.39M
Days sales outstanding
640.121.66K141.1762.2498.43
Days payables outstanding
714.67193.98146531.97191.43
Days of inventory on hand
748.93824.55227.4138.12101.05
Receivables turnover
0.570.222.595.863.71
Payables turnover
0.511.882.50.691.91
Inventory turnover
0.490.441.612.643.61
ROE
-2.25-0.87-1.18-0.58-0.23
Capex per share
-0.04-0.04-0.1-0.04-0.05

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-06-302021-09-302022-03-312022-06-30 2022-09-30
Revenue per share
0.410.280.30.330.36
Net income per share
-0.19-0.24-0.38-0.25-0.22
Operating cash flow per share
-0.16-0.02-0.38-0.14-0.63
Free cash flow per share
-0.17-0.03-0.38-0.15-0.64
Cash per share
4.453.623.343.383.37
Book value per share
4.654.483.923.713.52
Tangible book value per share
4.634.463.913.693.51
Share holders equity per share
4.654.483.923.713.52
Interest debt per share
0.040.040.030.020.02
Market cap
510.14M441.32M211.47M118.61M131.79M
Enterprise value
400.27M381.95M188.67M84.41M108.58M
P/E ratio
-27.03-18.55-5.59-4.74-5.9
Price to sales ratio
49.5162.8728.0514.2314.49
POCF ratio
-129.12-771.55-22.57-33.82-8.42
PFCF ratio
-122.87-668.67-22.39-31.71-8.22
P/B Ratio
4.413.962.161.281.5
PTB ratio
4.413.962.161.281.5
EV to sales
38.8554.4125.0310.1311.94
Enterprise value over EBITDA
-88.42-66.32-20.3-13.8-21.08
EV to operating cash flow
-101.31-667.74-20.14-24.07-6.94
EV to free cash flow
-96.41-578.71-19.97-22.56-6.77
Earnings yield
-0.01-0.01-0.04-0.05-0.04
Free cash flow yield
-0.010-0.04-0.03-0.12
Debt to equity
0.010.010.010.010
Debt to assets
0.080.080.080.10.12
Net debt to EBITDA
24.2710.312.455.594.5
Current ratio
16.4213.7713.9611.649.64
Interest coverage
-522.67-6610-1.59K-1.11K
Income quality
0.840.10.990.562.8
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.510.7610.660.55
Research and developement to revenue
0.390.480.480.370.42
Intangibles to total assets
00000
Capex to operating cash flow
0.050.150.010.070.02
Capex to revenue
-0.02-0.01-0.01-0.03-0.04
Capex to depreciation
-1.15-0.51-0.47-1.71-0.9
Stock based compensation to revenue
0.140.260.390.170.64
Graham number
4.464.95.794.574.21
ROIC
-0.04-0.05-0.09-0.07-0.07
Return on tangible assets
-0.04-0.05-0.09-0.06-0.06
Graham Net
4.333.383.163.153.04
Working capital
113.94M90.08M84.19M83.92M82.21M
Tangible asset value
115.18M111.02M97.4M92.13M87.81M
Net current asset value
111.48M87.45M82.01M81.7M80.05M
Invested capital
0.010.010.010.010
Average receivables
6.14M4.07M4.35M4.39M3.97M
Average payables
2.81M2.47M2.45M2.5M0
Average inventory
1.83M1.96M1.91M2.02M1.99M
Days sales outstanding
68.8548.1951.4947.3735.17
Days payables outstanding
136.78201.76121.33162.010
Days of inventory on hand
72.2156.5191.27131.3115.29
Receivables turnover
1.311.871.751.92.56
Payables turnover
0.660.450.740.560
Inventory turnover
1.250.580.990.690.78
ROE
-0.04-0.05-0.1-0.07-0.06
Capex per share
-0.0100-0.01-0.02

Frequently Asked Questions

What is AVITA Medical, Inc. stock symbol ?

AVITA Medical, Inc. is a US stock , located in Valencia california of California and trading under the symbol RCEL

What is AVITA Medical, Inc. stock quote today ?

AVITA Medical, Inc. stock price is $6.7 today.

Is AVITA Medical, Inc. stock public?

Yes, AVITA Medical, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap